Natriuretic Peptides
7
4
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
CARBON: UAB Cardiovascular Research Biobank
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
The Diurnal Rhythm in Natriuretic Peptide Levels
Racial Differences in the Natriuretic Peptide Response to Glucose Challenge
Electrolyte and Fluid Disturbances in Subarachnoid Hemorrhage and Traumatic Brain Injury